US Stock Insider Trading | MeiraGTx Holdings disclosed 5 insider transactions on February 23

K-LinePoet · 2026-02-27T11:46:57+00:00

MeiraGTx Holdings disclosed insider trading activities on February 23, 2026, with Director Forbes Alexandria selling 33,000 shares on February 21. Recently, several executives have also engaged in similar transactions, totaling hundreds of thousands of dollars. The company focuses on gene therapy and is dedicated to addressing various medical needs.

K-LinePoet

2026-02-27 11:46:57

Abstract generation in progress

On February 23, 2026, MeiraGTx Holdings (MGTX) disclosed five insider transactions. Director Forbes Alexandria sold 33,000 shares on February 21, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Giroux Richard	February 21, 2026	Sell	31,700	7.45	236,400
February 23, 2026	Executive	Naylor Stuart	February 21, 2026	Sell	11,800	7.45	87,500
February 23, 2026	Executive	Wollin Robert J	February 21, 2026	Sell	5,949	7.45	44,300
February 23, 2026	Director	Forbes Alexandria	February 21, 2026	Sell	33,000	7.45	246,200
February 23, 2026	Executive	Zeldin Robert K	February 21, 2026	Sell	2,952	7.45	22,000
January 21, 2026	Executive	Naylor Stuart	January 17, 2026	Sell	35,300	7.42	261,600
January 21, 2026	Executive	Giroux Richard	January 17, 2026	Sell	163,900	7.42	1,216,300
January 21, 2026	Director	Forbes Alexandria	January 17, 2026	Sell	163,900	7.42	1,216,300
January 21, 2026	Executive	Wollin Robert J	January 17, 2026	Sell	27,200	7.42	201,900
January 8, 2026	Executive	Naylor Stuart	January 7, 2026	Sell	17,600	7.73	136,200

[Company Profile]

MeiraGTx Holdings plc was incorporated on May 1, 2018, under the laws of the Cayman Islands. The company is a vertically integrated clinical-stage gene therapy company with six clinical development programs and a broad pipeline of preclinical and research projects. It possesses core capabilities in viral vector design and optimization, as well as gene therapy manufacturing, and has a potential translational gene regulation platform technology that allows precise, dose-responsive control of gene expression via oral small molecules, with a dynamic range exceeding 5,000-fold. The company’s initial focus is on three unmet medical needs: ocular diseases—including inherited retinal diseases, large degenerative eye diseases, neurodegenerative diseases, and severe dry eye syndrome.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.